Etranacogene Dezaparvovec治疗血友病B研究的最终分析
这项开放标签3期研究在54例男性血友病B患者中评估单次输注etranacogene dezaparvovec的5年疗效与安全性。调整后年化出血率从导入期的4.16降至治疗后第7至60个月的1.52,降幅63%(95%CI 24至82);5年时平均因子IX活性为36.1±15.7 IU/dL,外源性因子IX消耗减少96%。
要点
- 调整后年化出血率从导入期4.16降至第7至60个月1.52,降幅63%(95%CI 24至82)。
- 5年时平均因子IX活性36.1±15.7 IU/dL,内源性表达保持稳定。
- 外源性因子IX年消耗从257339 IU降至10924 IU,减少96%。
核心结论
- 单次输注etranacogene dezaparvovec后5年内观察到持续的内源性因子IX表达和低年化出血率。
研究设计与样本
- 开放标签3期研究,男性血友病B患者(因子IX活性≤2 IU/dL)在≥6个月因子IX预防导入期后接受单次etranacogene dezaparvovec输注,无论是否存在AAV5中和抗体。
- 预设5年分析包括调整后年化出血率(基因治疗后第7至60个月与导入期之差)、因子IX表达和安全性结局,全分析人群54例。
主要发现
- 全分析人群54例中,所有出血事件的调整后年化出血率导入期为4.16,基因治疗后第7至60个月为1.52,降低63%(95%CI 24至82)。
- 5年随访期间内源性因子IX表达保持稳定;5年时平均(±SD)因子IX活性为36.1±15.7 IU/dL。
- 常规预防和出血事件治疗的平均外源性因子IX消耗减少96%,从导入期每年257339 IU降至基因治疗后第7至60个月每年10924 IU。
- 基线存在与不存在AAV5中和抗体的参与者之间疗效无实质性差异。
- 第6个月后可能与治疗相关的不良事件罕见。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prophylactic treatment for hemophilia B necessitates lifelong, regular intravenous factor IX infusions. Gene therapy offers the possibility of a single-dose treatment that produces durable endogenous factor IX expression and disease control. Etranacogene dezaparvovec comprises an adeno-associated virus serotype 5 (AAV5) vector and the highly active Padua factor IX variant. The primary analysis of this study showed that etranacogene dezaparvovec reduced annualized bleeding rates and adverse events were mainly of low-grade severity. Final data from 5 years of follow-up are now available. METHODS: In this open-label, phase 3 study, after a lead-in period (≥6 months) of factor IX prophylaxis, we administered a single infusion of etranacogene dezaparvovec in men with hemophilia B (factor IX activity level, ≤2 IU per deciliter), regardless of preexisting AAV5 neutralizing antibodies. The prespecified 5-year analyses included adjusted annualized bleeding rates (difference between the post-treatment period of months 7 through 60 after gene therapy and the lead-in period), factor IX expression, and safety outcomes. RESULTS: In the full analysis population (54 participants), the adjusted annualized bleeding rate for all bleeding events was 4.16 during the lead-in period and 1.52 during months 7 through 60 after gene therapy, a reduction of 63% (95% confidence interval, 24 to 82). During the 5-year follow-up period, endogenous factor IX expression remained stable; at 5 years, the mean (±SD) factor IX activity level was 36.1±15.7 IU per deciliter and the mean exogenous factor IX consumption for routine prophylaxis and treatment of bleeding events had decreased by 96%, from 257,339 IU per year during the lead-in period to 10,924 IU per year during months 7 through 60 after gene therapy. Efficacy did not differ substantially between participants with and those without AAV5 neutralizing antibodies at baseline. Adverse events that were possibly related to treatment were rare after month 6. CONCLUSIONS: Sustained endogenous factor IX expression and low annualized bleeding rates over a 5-year period were observed after an infusion of etranacogene dezaparvovec. (Funded by uniQure and CSL Behring; HOPE-B ClinicalTrials.gov number, NCT03569891.).
引用
- Pipe SW, Miesbach W, Recht M, et al. Final Analysis of a Study of Etranacogene Dezaparvovec for Hemophilia B. N Engl J Med. 2025. PMID: 41358585. doi:10.1056/NEJMoa2514332
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。